Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/8/2025 | $60.00 | Equal-Weight | Morgan Stanley |
| 5/1/2025 | Overweight → Equal Weight | Wells Fargo | |
| 3/26/2025 | $68.00 → $71.00 | Neutral → Overweight | Analyst |
| 3/5/2025 | Buy → Neutral | Seaport Research Partners | |
| 8/8/2024 | $90.00 → $89.00 | Underweight → Neutral | JP Morgan |
| 4/11/2024 | $100.00 → $112.00 | Equal Weight → Overweight | Wells Fargo |
| 3/14/2024 | $100.00 → $126.00 | Hold → Buy | Jefferies |
| 3/1/2024 | $108.00 | Outperform | Wolfe Research |
8-K - ASHLAND INC. (0001674862) (Filer)
SCHEDULE 13G - ASHLAND INC. (0001674862) (Subject)
10-Q - ASHLAND INC. (0001674862) (Filer)
Wilmington, Del., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced that a production unit at its Calvert City, Kentucky manufacturing facility is currently offline following an equipment-related incident that occurred earlier this month. The affected unit was safely shut down for repairs and fabrication and installation of new equipment will be required to restore full functionality. Based on current assessments, repairs are expected to be completed during fiscal Q1 2026, primarily due to the lead time required for sourcing parts. The damage and repair activities are confined to Ashland's upstream operations. While a production unit will be temporarily shut dow
WILMINGTON, Del., Aug. 08, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.415 cents per share on the company's common stock. The dividend will be payable on September 15, 2025, to stockholders of record at the close of business on September 1, 2025. As of July 31, 2025, there were 45,709,431 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural
Sales of $463 million, down 15 percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC), Nutraceuticals and Avoca portfolio optimization initiatives (collectively, Portfolio Optimization) reduced overall sales by approximately $53 million or 10 percent versus the prior-year quarter. Excluding these initiatives, sales declined five percentLoss from continuing operations of $719 million, or $(15.70) per diluted share, primarily reflecting a non-cash goodwill impairment charge of $706 millionAdjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $48 million, or $1.04 per diluted shareNet loss of $742 million, or
Morgan Stanley initiated coverage of Ashland with a rating of Equal-Weight and set a new price target of $60.00
Wells Fargo downgraded Ashland from Overweight to Equal Weight
Analyst upgraded Ashland from Neutral to Overweight and set a new price target of $71.00 from $68.00 previously
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
WILMINGTON, Del., May 05, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that Kevin Willis, senior vice president and chief financial officer, has decided to leave Ashland to pursue another opportunity. His last day with the company will be May 16, 2025. Willis joined Ashland in 1987 as an associate auditor in the internal audit department. He has served in various management positions of increasing responsibility, including leading teams on major projects in the business services, information technology, accounting and finance areas. Willis' departure is not the result of any disagreement with the company related to its financial statements, internal control over finan
Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), the former nutraceuticals business of Ashland Inc. (NYSE:ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Company also offers custom formulation and contract manufactu
Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE:ASH) by Turnspire Capital Partners LLC ("Turnspire"). Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuticals. From its manufacturing facilities in New Jersey and Utah in the United States and Tamaulipas, Mexico, Pharmachem produces a wide range of proprietary and private labeled products used in many applications, including hydratio
WILMINGTON, Del., Aug. 08, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.415 cents per share on the company's common stock. The dividend will be payable on September 15, 2025, to stockholders of record at the close of business on September 1, 2025. As of July 31, 2025, there were 45,709,431 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural
Sales of $463 million, down 15 percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC), Nutraceuticals and Avoca portfolio optimization initiatives (collectively, Portfolio Optimization) reduced overall sales by approximately $53 million or 10 percent versus the prior-year quarter. Excluding these initiatives, sales declined five percentLoss from continuing operations of $719 million, or $(15.70) per diluted share, primarily reflecting a non-cash goodwill impairment charge of $706 millionAdjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $48 million, or $1.04 per diluted shareNet loss of $742 million, or
WILMINGTON, Del., July 16, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its third-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Tuesday, July 29, 2025. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 10 a.m. ET on Wednesday, July 30. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerWilliam Whitaker, interim chief financial officerDago C
SC 13G - ASHLAND INC. (0001674862) (Subject)
SC 13G/A - ASHLAND INC. (0001674862) (Subject)
SC 13D/A - ASHLAND INC. (0001674862) (Subject)